CRO giant Parexel has seen its chief financial officer and senior vice president Ingo Bank resign from the company over the weekend, according to a SEC filing.
Parexel, which is set to post its Q4/FY financial results in just over two weeks’ time (August 3), said Bank had left “in order to take a senior leadership role in another company,” without specifying where.
The Waltham, MA-based CRO said it intends quickly start looking for a permanent CFO. Bank will however continue to be an employee until mid-August, in order to help “assist in the transition of his position,” the SEC filing said.
Emma Reeve has been named interim CFO. She has been the company’s corporate VP since 2014.
Parexel said that Reeve has more than 20 years of experience in life sciences financial management, having worked as head of finance and administration for Novartis ($NVS), and has also served as biotech CFO before, notably at Inotek Pharmaceuticals.
Last October, Parexel narrowed its outlook for fiscal 2016, reducing its revenue target by about 2% at midpoint to around $2.14 billion amid sliding profits.
The CRO has also been in the process of shedding around 850 jobs during the past year, with the goal of saving between $20 million and $30 million a year starting from 2016.
By Ben Adams
Source: Fierce Biotech
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.